0.252
-0.01 (-3.19%)
Penutupan Terdahulu | 0.260 |
Buka | 0.252 |
Jumlah Dagangan | 366,019 |
Purata Dagangan (3B) | 938,318 |
Modal Pasaran | 8,357,645 |
Harga / Buku (P/B) | 0.950 |
Julat 52 Minggu | |
Tarikh Pendapatan | 6 May 2025 - 12 May 2025 |
EPS Cair (TTM) | -2.51 |
Nisbah Semasa (MRQ) | 5.29 |
Aliran Tunai Operasi (OCF TTM) | -56.79 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -30.05 M |
Pulangan Atas Aset (ROA TTM) | -88.24% |
Pulangan Atas Ekuiti (ROE TTM) | -160.26% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Menurun | Menurun |
Biotechnology (Global) | Menurun | Menurun | |
Stok | Relmada Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
Konsensus Penganalisis | -2.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 0.5 |
Purata Bergerak Teknikal | 0.0 |
Osilator Teknikal | 2.0 |
Purata | 0.13 |
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Value |
% Dimiliki oleh Orang Dalam | 17.02% |
% Dimiliki oleh Institusi | 33.47% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Parsons Capital Management Inc/Ri | 31 Dec 2024 | 163,336 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
12 May 2025 | Pengumuman | Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update |
08 May 2025 | Pengumuman | Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 |
28 Apr 2025 | Pengumuman | Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 |
27 Apr 2025 | Pengumuman | UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 |
24 Apr 2025 | Pengumuman | Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data |
14 Apr 2025 | Pengumuman | Relmada Therapeutics To Present NDV-01 Data at AUA2025 |
27 Mar 2025 | Pengumuman | Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update |
26 Mar 2025 | Pengumuman | Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025 |
25 Mar 2025 | Pengumuman | Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |